Cytosorbents (CTSO) Receivables (2011 - 2026)

Cytosorbents (CTSO) has reported Receivables for 16 consecutive years, with $6.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables fell 52.81% year-over-year to $6.8 million; the trailing twelve-month figure through Jun 2026 stood at $6.8 million (down 52.81% YoY), and the FY2025 full-year result was $14.7 million, up 13.58% from the prior year.
• Receivables fell to $6.8 million in Q2 2026 per CTSO's latest filing, from $14.1 million in the prior quarter.
• Across five years, Receivables topped out at $14.7 million in Q4 2025 and bottomed at $6.8 million in Q2 2026.
• Historically, Receivables has averaged $11.4 million across 5 years, with a median of $11.6 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Receivables grew 26.09% in 2022, then plunged 52.81% in 2026.
• Over 5 years, Receivables stood at $9.5 million in 2022, then gained by 19.71% to $11.4 million in 2023, then advanced by 13.76% to $12.9 million in 2024, then rose by 13.58% to $14.7 million in 2025, then sank by 53.76% to $6.8 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $6.8 million, $14.1 million, and $14.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.